ArticlePLoS neglected tropical diseases2026
Co-designing the 'LEAD' strategy: A theory-informed stakeholder-led behavioural intervention to improve mass drug administration compliance for lymphatic filariasis elimination in an urban block of Odisha, India.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSustained compliance with Mass Drug Administration (MDA) is essential for interrupting transmission of Lymphatic filariasis (LF). However, behavioural and system-level barriers persist to hinder its uptake. We aimed to explore determinants of MDA participation using behavioural frameworks and to co-design a theory-informed, stakeholder-led intervention to enhance MDA compliance.
methodsA mixed-methods formative study was conducted between January and June 2025 in an LF-endemic block of Odisha, India. The quantitative component comprised a community-based KAP survey(n = 400) assessing knowledge, MDA coverage, and compliance. The qualitative component involved two focus group discussions and three key informant interviews with frontline health workers, community members, and programme supervisors to explore perceptions, barriers, and delivery challenges. Findings were mapped to the Theoretical Domains Framework (TDF) and the Capability-Opportunity-Motivation-Behaviour (COM-B) model to identify behavioural determinants and inform intervention design. Two stakeholder workshops were subsequently held to co-develop a contextually relevant implementation package.
resultsAmong 400 survey respondents (mean age 46 years; 52% female), MDA coverage was 81% (n = 322), while MDA compliance was 57% (n = 229). The main reasons for non-compliance included fear of side effects (40%), misconceptions about the disease, and mistrust of government medicines. Qualitative findings revealed barriers in Capability (limited awareness, inadequate communication skills), Opportunity (weak supervision, irregular supply, competing workloads), and Motivation (low risk perception, fear, misinformation). Stakeholders jointly developed the 'LEAD' strategy (Leveraging existing community platforms, Education in schools, Awareness via digital media, and Delivery through Frontline Health Workers). LEAD integrates interpersonal communication by health workers, school-based education using children as health messengers, community mobilisation through self-help groups, and message reinforcement via digital media. CONCLUSION/SIGNIFICANCE: The study identified multi-level behavioural and operational determinants influencing MDA uptake in an endemic Indian setting. The LEAD package will be evaluated in the next phase of our study for feasibility, acceptability, and effectiveness in strengthening India's LF elimination efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.